Mes compétences :
Pharmacologie
Pharmacocinétique
Pharmacie Clinique
Modelisation PK/PD
Entreprises
Université de Bourgogne
- MCU-PH (Associate Professor) en Pharmacologie/Pharmacien Hospitalier
Dijon 2015 - maintenant- Co-director of the speciality Industry at the Faculty of Pharmacy
- Clinical Pharmacist at the Centre Georges-Francois Leclerc (Dijon's Cancer Institute): expert in the therapeutic use of medications; routinely provide medication therapy evaluations and recommendations to patients and other health care professionals; primary source of scientifically valid information and advice regarding the safe, appropriate, and cost-effective use of medications
- Lectures in Clinical Pharmacy, Pharmacology and Pharmacokinetics
Centre Georges-François Leclerc - Université de Bourgogne
- Assistant Hospitalo-Universitaire
2012 - 2015- Co-director of the speciality Industry at the Faculty of Pharmacy
- Clinical Pharmacist at the Centre Georges-Francois Leclerc (Dijon's Cancer Institute): expert in the therapeutic use of medications; routinely provide medication therapy evaluations and recommendations to patients and other health care professionals; primary source of scientifically valid information and advice regarding the safe, appropriate, and cost-effective use of medications
- Lectures in Clinical Pharmacy, Pharmacology and Pharmacokinetics
Novartis
- Pharmacocineticien Senior
RUEIL MALMAISON 2011 - 2012Clinical Pharmacology representative (CPR) in teams at project level, clinical team level and study level for several projects from Phase I to Phase III.
CPR for Phase I FIM studies
Design of concept protocols, development of full clinical protocols, implementation of the studies, analysis (as applicable), interpretation of data (and communication to management/partners), report writing
Contribution as CPR to all study-related documents (e.g. CRFs, regulatory documents etc.)
Involvement in multi-site, multi-country Phase II / III studies as CPR, in particular in relation to implementation of appropriate PK sampling for population PK and PK/PD analyses
Main experience in oncology
Regulatory experience: preparation of regulatory documents (IB, IMPD) and documents for regulatory consultation (Type C meeting)
Novartis
- Postdoc en pharmacologie clinique oncologique
RUEIL MALMAISON 2010 - 2011Mise au point d'un modèle de pharmacocinétique de population permettant de décrire un phénomène de compétition de la liaison aux protéines plasmatiques entre une molécule mère et ses deux principaux métabolites.
Institut Claudius-Regaud
- Doctorant en pharmacocinetique
2008 - 2010Détermination des caractéristiques des patients impliquées dans les toxicités hématologiques consécutives à l'administration de médicaments anticancéreux : apport de la méthodologie de pharmacocinétique/pharmacodynamique de population. Sous la direction d'Étienne Chatelut et de Didier Concordet
Université Paul Sabatier - Faculté de Pharmacie
- Moniteur de l'Enseignement Supérieur
2008 - 2010Enseignant en pharmacologie et pharmacocinétique
CHU de Toulouse
- Interne en pharmacie spécialisée
